Patents by Inventor Yoshihisa Manabe

Yoshihisa Manabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7960393
    Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: June 14, 2011
    Assignee: Actimis Pharmaceuticals, Inc.
    Inventors: Tai-wei Ly, Yuji Koriyama, Takashi Yoshino, Hiroki Sato, Kazuho Tanaka, Hiromi Sugimoto, Yoshihisa Manabe, Kevin Bacon, Klaus Urbahns, Masanori Seki, Takuya Shintani
  • Publication number: 20100322980
    Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    Type: Application
    Filed: August 25, 2010
    Publication date: December 23, 2010
    Inventors: Tai-wei Ly, Yuji Koriyama, Takashi Yoshino, Hiroki Sato, Kazuho Tanaka, Hiromi Sugimoto, Yoshihisa Manabe, Kevin Bacon, Klaus Urbahns, Masanori Seki, Takuya Shintani
  • Patent number: 7812160
    Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: October 12, 2010
    Assignee: Actimis Pharmaceuticals, Inc.
    Inventors: Tai-wei Ly, Yuji Koriyama, Takashi Yoshino, Hiroki Sato, Kazuho Tanaka, Hiromi Sugimoto, Yoshihisa Manabe, Kevin Bacon, Klaus Urbahns, Masanori Seki, Takuya Shintani
  • Publication number: 20100145298
    Abstract: An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.
    Type: Application
    Filed: February 12, 2010
    Publication date: June 10, 2010
    Inventors: Nobuaki HORI, Yoshihisa Manabe, Yuko Suka, Toshiya Kai, Seiji Nishida, Naohisa Katayama
  • Publication number: 20080193516
    Abstract: An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.
    Type: Application
    Filed: February 14, 2008
    Publication date: August 14, 2008
    Inventors: Nobuaki HORI, Yoshihisa Manabe, Yuko Suka, Toshiya Kai, Seiji Nishida, Naohisa Katayama
  • Publication number: 20070129355
    Abstract: The present invention relates to a pyrimidine derivative of the formula (I) and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The pyrimidine derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
    Type: Application
    Filed: April 14, 2004
    Publication date: June 7, 2007
    Applicants: ACTIMIS PHARMACEUTICALS, INC., BAYER AG, BAYER HEALTH CARE AG
    Inventors: Tai-wei Ly, Yuji Koriyama, Takashi Yoshino, Hiroki Sato, Kazuho Tanaka, Hiromi Sugimoto, Yoshihisa Manabe, Kevin Bacon, Klaus Urbahns, Masanori Seki, Takuya Shintani